S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
OTCMKTS:GNMSF

Genmab A/S - GNMSF Stock Forecast, Price & News

$392.50
+8.80 (+2.29%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$385.00
▼
$393.10
50-Day Range
$383.70
▼
$462.90
52-Week Range
$260.25
▼
$470.50
Volume
131 shs
Average Volume
248 shs
Market Capitalization
$25.66 billion
P/E Ratio
32.36
Dividend Yield
N/A
Price Target
N/A

GNMSF stock logo

About Genmab A/S (OTCMKTS:GNMSF) Stock

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.

Receive GNMSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

GNMSF Stock News Headlines

January 23, 2023 | finance.yahoo.com
GILD or GMAB: Which Is the Better Value Stock Right Now?
January 19, 2023 | finance.yahoo.com
Correction to Company Announcement No. 1 of January 3, 2023
January 29, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
January 2, 2023 | finance.yahoo.com
Genmab to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 12, 2022 | finance.yahoo.com
Is Elevance Health, Inc. (ELV) Stock Outpacing Its Medical Peers This Year?
December 11, 2022 | finance.yahoo.com
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting
December 3, 2022 | finance.yahoo.com
Top Stocks In Multiple Industries Build Bases As Market Gains Strength
December 2, 2022 | finance.yahoo.com
Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue?
January 29, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
December 1, 2022 | finance.yahoo.com
5 Top Stocks to Tap Earnings Beat Potential
November 23, 2022 | finance.yahoo.com
15 Biggest European Pharmaceutical Companies
November 22, 2022 | finance.yahoo.com
AbbVie (ABBV) BLA for Epcoritamab Gets FDA Priority Tag
November 21, 2022 | finance.yahoo.com
Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
November 8, 2022 | finance.yahoo.com
Is Genmab (GMAB) Outperforming Other Medical Stocks This Year?
October 25, 2022 | marketwatch.com
Scancell Shares Rise on Licensing Deal With Genmab
October 21, 2022 | finance.yahoo.com
4 Biotech Stocks Set to Outpace Q3 Earnings Estimates
September 6, 2022 | finance.yahoo.com
Genmab to Present at Morgan Stanley 20th Annual Global Healthcare Conference
September 3, 2022 | finance.yahoo.com
Genmab A/S (GNMSF)
August 5, 2022 | finance.yahoo.com
Genmab, BioNTech Join Forces For Cancer Immunotherapy Candidates
August 5, 2022 | benzinga.com
BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
July 18, 2022 | finance.yahoo.com
AbbVie To Submit European Application For Epcoritamab In Lymphoma Setting Later In 2022
June 13, 2022 | finance.yahoo.com
AbbVie - Genmab Present Epcoritamab Data From Lymphoma Trial
June 11, 2022 | finance.yahoo.com
Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium
June 8, 2022 | finance.yahoo.com
Genmab to Participate in a Fireside Chat at the Goldman Sachs 43rd Annual Global Healthcare Conference
May 11, 2022 | finance.yahoo.com
Genmab Announces Financial Results for the First Quarter of 2022
May 10, 2022 | finance.yahoo.com
Should You Buy Genmab (GMAB) Ahead of Earnings?
April 14, 2022 | finance.yahoo.com
Genmab (GMAB), AbbVie's Epcoritamab Successful in LBCL Study
See More Headlines
Receive GNMSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

GNMSF Company Calendar

Last Earnings
11/09/2022
Today
1/29/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:GNMSF
CUSIP
N/A
CIK
1434265
Web
www.genmab.com
Phone
(457) 020-2728
Fax
45-7020-2729
Employees
1,212
Year Founded
1999

Profitability

EPS (Most Recent Fiscal Year)
$12.13
Trailing P/E Ratio
32.36
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$478.57 million
Net Margins
46.32%
Pretax Margin
60.14%
Return on Equity
22.78%
Return on Assets
20.33%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.62
Quick Ratio
9.62

Sales & Book Value

Annual Sales
$1.35 billion
Price / Sales
19.02
Cash Flow
$7.92 per share
Price / Cash Flow
49.54
Book Value
$54.02 per share
Price / Book
7.27

Miscellaneous

Outstanding Shares
65,370,000
Free Float
64,363,000
Market Cap
$25.66 billion
Optionable
Not Optionable
Beta
0.91

Social Links


Key Executives

  • Jan G. J. van de Winkel
    President & Chief Executive Officer
  • Anthony Mancini
    Chief Operating Officer & Executive Vice President
  • Anthony Pagano
    Chief Financial Officer & Executive Vice President
  • Tahamtan Ahmadi
    Chief Medical Officer & Executive Vice President
  • Martin Schultz
    Non-Independent Director

Key Competitors

View All Competitors













GNMSF Stock - Frequently Asked Questions

How have GNMSF shares performed in 2023?

Genmab A/S's stock was trading at $427.50 at the beginning of the year. Since then, GNMSF stock has decreased by 8.2% and is now trading at $392.50.
View the best growth stocks for 2023 here.

Are investors shorting Genmab A/S?

Genmab A/S saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 67,100 shares, an increase of 527.1% from the December 31st total of 10,700 shares. Based on an average trading volume of 1,600 shares, the days-to-cover ratio is currently 41.9 days.
View Genmab A/S's Short Interest.

How were Genmab A/S's earnings last quarter?

Genmab A/S (OTCMKTS:GNMSF) announced its quarterly earnings results on Wednesday, November, 9th. The company reported $5.31 EPS for the quarter. The company earned $553.71 million during the quarter. Genmab A/S had a trailing twelve-month return on equity of 22.78% and a net margin of 46.32%.

What is Genmab A/S's stock symbol?

Genmab A/S trades on the OTCMKTS under the ticker symbol "GNMSF."

How do I buy shares of Genmab A/S?

Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genmab A/S's stock price today?

One share of GNMSF stock can currently be purchased for approximately $392.50.

How much money does Genmab A/S make?

Genmab A/S (OTCMKTS:GNMSF) has a market capitalization of $25.66 billion and generates $1.35 billion in revenue each year. The company earns $478.57 million in net income (profit) each year or $12.13 on an earnings per share basis.

How many employees does Genmab A/S have?

The company employs 1,212 workers across the globe.

How can I contact Genmab A/S?

Genmab A/S's mailing address is KALVEBOD BRYGGE 43, COPENHAGEN G7, 1560. The official website for the company is www.genmab.com. The company can be reached via phone at (457) 020-2728, via email at acn@genmab.com, or via fax at 45-7020-2729.

This page (OTCMKTS:GNMSF) was last updated on 1/29/2023 by MarketBeat.com Staff